Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: a patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials Moura, F., Wiviott, S., Chertow, G., Dwyer, J., Gause-Nilsson, Johansson, P., Langkilde, A., McMurray, J., Mosenzon, O., Raz, Rossing, P., Wheeler, D., Sabatine, M., Heerspink, H. OXFORD UNIV PRESS. 2022: 2407

View details for Web of Science ID 000894947901652